IBDEI0I5 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7910,2)
 ;;=^5002534
 ;;^UTILITY(U,$J,358.3,7911,0)
 ;;=T81.33XA^^65^512^27
 ;;^UTILITY(U,$J,358.3,7911,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7911,1,3,0)
 ;;=3^Disruption Traumatic Inj/Wound Repair,Init Encntr
 ;;^UTILITY(U,$J,358.3,7911,1,4,0)
 ;;=4^T81.33XA
 ;;^UTILITY(U,$J,358.3,7911,2)
 ;;=^5054476
 ;;^UTILITY(U,$J,358.3,7912,0)
 ;;=L60.3^^65^512^30
 ;;^UTILITY(U,$J,358.3,7912,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7912,1,3,0)
 ;;=3^Dystrophic Nails
 ;;^UTILITY(U,$J,358.3,7912,1,4,0)
 ;;=4^L60.3
 ;;^UTILITY(U,$J,358.3,7912,2)
 ;;=^5009236
 ;;^UTILITY(U,$J,358.3,7913,0)
 ;;=M71.30^^65^512^25
 ;;^UTILITY(U,$J,358.3,7913,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7913,1,3,0)
 ;;=3^Digital Mucous Cyst
 ;;^UTILITY(U,$J,358.3,7913,1,4,0)
 ;;=4^M71.30
 ;;^UTILITY(U,$J,358.3,7913,2)
 ;;=^5013149
 ;;^UTILITY(U,$J,358.3,7914,0)
 ;;=L30.4^^65^513^10
 ;;^UTILITY(U,$J,358.3,7914,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7914,1,3,0)
 ;;=3^Erythema Intertrigo
 ;;^UTILITY(U,$J,358.3,7914,1,4,0)
 ;;=4^L30.4
 ;;^UTILITY(U,$J,358.3,7914,2)
 ;;=^5009157
 ;;^UTILITY(U,$J,358.3,7915,0)
 ;;=R60.0^^65^513^6
 ;;^UTILITY(U,$J,358.3,7915,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7915,1,3,0)
 ;;=3^Edema,Localized
 ;;^UTILITY(U,$J,358.3,7915,1,4,0)
 ;;=4^R60.0
 ;;^UTILITY(U,$J,358.3,7915,2)
 ;;=^5019532
 ;;^UTILITY(U,$J,358.3,7916,0)
 ;;=L53.0^^65^513^14
 ;;^UTILITY(U,$J,358.3,7916,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7916,1,3,0)
 ;;=3^Erythema Toxic
 ;;^UTILITY(U,$J,358.3,7916,1,4,0)
 ;;=4^L53.0
 ;;^UTILITY(U,$J,358.3,7916,2)
 ;;=^5009207
 ;;^UTILITY(U,$J,358.3,7917,0)
 ;;=L53.1^^65^513^9
 ;;^UTILITY(U,$J,358.3,7917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7917,1,3,0)
 ;;=3^Erythema Annulare Centrifugum
 ;;^UTILITY(U,$J,358.3,7917,1,4,0)
 ;;=4^L53.1
 ;;^UTILITY(U,$J,358.3,7917,2)
 ;;=^5009208
 ;;^UTILITY(U,$J,358.3,7918,0)
 ;;=L51.9^^65^513^12
 ;;^UTILITY(U,$J,358.3,7918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7918,1,3,0)
 ;;=3^Erythema Multiforme,Unspec
 ;;^UTILITY(U,$J,358.3,7918,1,4,0)
 ;;=4^L51.9
 ;;^UTILITY(U,$J,358.3,7918,2)
 ;;=^336759
 ;;^UTILITY(U,$J,358.3,7919,0)
 ;;=L12.35^^65^513^8
 ;;^UTILITY(U,$J,358.3,7919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7919,1,3,0)
 ;;=3^Epidermolysis Bullosa,Acquired
 ;;^UTILITY(U,$J,358.3,7919,1,4,0)
 ;;=4^L12.35
 ;;^UTILITY(U,$J,358.3,7919,2)
 ;;=^5009100
 ;;^UTILITY(U,$J,358.3,7920,0)
 ;;=L52.^^65^513^13
 ;;^UTILITY(U,$J,358.3,7920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7920,1,3,0)
 ;;=3^Erythema Nodosum
 ;;^UTILITY(U,$J,358.3,7920,1,4,0)
 ;;=4^L52.
 ;;^UTILITY(U,$J,358.3,7920,2)
 ;;=^42065
 ;;^UTILITY(U,$J,358.3,7921,0)
 ;;=L49.0^^65^513^26
 ;;^UTILITY(U,$J,358.3,7921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7921,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ < 10% Body Surface
 ;;^UTILITY(U,$J,358.3,7921,1,4,0)
 ;;=4^L49.0
 ;;^UTILITY(U,$J,358.3,7921,2)
 ;;=^5009190
 ;;^UTILITY(U,$J,358.3,7922,0)
 ;;=L49.1^^65^513^17
 ;;^UTILITY(U,$J,358.3,7922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7922,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 10-19% Body Surface
 ;;^UTILITY(U,$J,358.3,7922,1,4,0)
 ;;=4^L49.1
 ;;^UTILITY(U,$J,358.3,7922,2)
 ;;=^5009191
 ;;^UTILITY(U,$J,358.3,7923,0)
 ;;=L49.2^^65^513^18
 ;;^UTILITY(U,$J,358.3,7923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7923,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 20-29% Body Surface
